PAPERZILLA
Crunching Academic Papers into Bite-sized Insights.
About
Sign Out
← Back to papers
Life Sciences › Neuroscience › Biological Psychiatry
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
★
★
★
★
☆
SHARE
Overview
Paper Summary
Conflicts of Interest
Identified Weaknesses
Rating Explanation
Good to know
Topic Hierarchy
File Information
Paper Summary
Paperzilla title
This Drug Could Be a Game-Changer for Depression and Anxiety
Edaravone (EDA) shows promise as a treatment for depression and anxiety. It works by activating a specific pathway in the brain (Sirt1/Nrf2/HO-1/Gpx4) and protecting brain cells from damage.
Possible Conflicts of Interest
The study was funded by the National Key Research and Development Program of China, the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences, and the Natural Science Foundation Project of China. No other potential conflicts of interest were identified.
Identified Weaknesses
Lack of control group for Gpx4 knockdown
The lack of a control group for the Gpx4 knockdown experiment makes it difficult to determine whether the observed effects are due to the knockdown itself or to other factors.
Only male mice used
The study only investigated the effects of EDA in male mice, so the findings may not be generalizable to females.
Single dose of EDA used
The study used a single dose of EDA, so it is unclear whether the observed effects are dose-dependent.
No long-term effects investigated
The study did not investigate the long-term effects of EDA treatment.
Rating Explanation
This is a well-conducted preclinical study with promising results. The study uses a well-established animal model of depression and employs a variety of behavioral tests to assess the effects of EDA. The study also investigates the molecular mechanisms underlying the effects of EDA. However, the study is limited by its preclinical nature and the lack of investigation into long-term effects or female subjects.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →
Topic Hierarchy
File Information
Original Title:
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
File Name:
s12974-022-02400-6.pdf
[download]
File Size:
16.39 MB
Uploaded:
July 14, 2025 at 11:21 AM
Privacy:
🌐 Public
© 2025 Paperzilla. All rights reserved.